| |
Tuesday, June 17, 2025 | 11am ET / 8am PT We invite you to join industry experts to explore advanced process analytical technologies (PAT), and how they are transforming bioprocessing. Register now.
|
|
Today’s Big NewsJun 13, 2025 |
|
Monday, June 16, 2025 | 12pm ET / 9am PT Join a candid and informative discussion between precision medicine experts. They will share lessons learned and concrete opportunities to transform clinical trial design, execution and outcomes. Register now.
|
|
| By Kevin Dunleavy Independent Sens. Bernie Sanders of Vermont and Angus King of Maine have introduced a bill that would ban pharmaceutical companies from advertising directly to consumers. The End Prescription Drug Ads Now Act would prohibit drugmakers from promoting prescription drugs through television, radio, print, digital platforms and social media. |
|
|
|
By Darren Incorvaia Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when deciding on a new tactical leader. The Big Pharma has hired physician-turned-analyst Chris Shibutani, M.D., as executive vice president and chief strategy officer, BMS announced on June 9. |
By Darren Incorvaia Johnson and Johnson is providing a first look at clinical data for its dual-targeting blood cancer CAR-T program. |
By Conor Hale Founded by the same group that helped launch the pulsed field ablation company Farapulse, Atraverse Medical plans to expand its commercial reach. |
|
Wednesday, June 18, 2025 | 12pm ET / 9am PT In this webinar, we will present two new methods for blood preservation that can be easily implemented at any clinical site just after the patient’s blood collection. Register to learn more.
|
|
By James Waldron AstraZeneca has returned to recent collaborator CSPC Pharmaceuticals with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases. |
By Zoey Becker Zusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), standing to replace the current surgical standard-of-care. |
By James Waldron Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. |
By Angus Liu Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the indication is limited to PD-L1-positive disease. |
By Darren Incorvaia,Zoey Becker After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan will head up the British Big Pharma’s vaccine and infectious disease R&D from Boston, working under Chief Scientific Officer Tony Wood, Ph.D. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we unpack Fierce Medtech's Fierce 15 and spotlight startups reimagining healthcare. |
|
|---|
|
|
|
Supported by 30 years of experience conducting complex Phase I & II clinical trials, QPS Miami supports special populations and diverse indications like NASH, diabetes, obesity and oncology. Learn More.
|
|
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
